Form 4: Cencora Director Acquires Shares via RSU Grant

Cencora Director Lauren M. Tyler acquired 105 shares of common stock through a Restricted Stock Unit grant, deferring delivery until 2030.

Summary

• Lauren M. Tyler, a Director of Cencora, Inc. (COR), acquired 105 shares of common stock.
• The acquisition occurred on August 1, 2025, at a price of $288.35 per share.
• This transaction represents a grant of Restricted Stock Units (RSUs) received in lieu of a $30,000 quarterly cash retainer.
• The shares are part of Cencora's Non-Employee Compensation Program.
• Delivery of these shares is deferred until March 1, 2030.
• Following this transaction, Lauren M. Tyler beneficially owns 2,980 shares of Cencora common stock directly.

Sentiment

Score: 7

Explanation: The filing indicates a routine, positive alignment of director and shareholder interests through equity compensation, with no negative implications. The deferral of shares is a standard retention mechanism.

Positives

• Director Lauren M. Tyler's acquisition of shares aligns her interests with shareholders, indicating confidence in the company's future.
• The use of Restricted Stock Units (RSUs) as compensation for non-employee directors is a common practice that promotes long-term alignment and retention.
• The deferral of share delivery until 2030 suggests a long-term commitment from the director.

Future Outlook

The deferral of share delivery until March 1, 2030, indicates a long-term retention strategy for the director and aligns their future interests with the company's performance.

Management Comments

• The grant of Restricted Stock Units was received in lieu of a $30,000 quarterly cash retainer per the Registrant's Non-Employee Compensation Program.

Industry Context

This transaction reflects a common practice in corporate governance where non-employee directors receive equity-based compensation, such as RSUs, to align their interests with long-term shareholder value. This is standard across many publicly traded companies, particularly in the healthcare or pharmaceutical distribution sector where Cencora operates.

Comparison to Industry Standards

• The practice of compensating non-employee directors with equity, specifically RSUs, is a widely adopted standard across industries, including healthcare and pharmaceutical distribution.
• Companies like Cardinal Health (CAH) and McKesson Corporation (MCK), direct competitors of Cencora, also utilize similar equity compensation programs for their non-executive directors to foster long-term alignment and retention.
• The specific value of the RSU grant ($30,000 quarterly retainer equivalent) is within the typical range for director compensation at large-cap companies, though exact comparisons would require detailed analysis of peer compensation disclosures.

Related Party Transactions

• The grant of Restricted Stock Units to a director in lieu of a cash retainer is a related party transaction, consistent with the company's Non-Employee Compensation Program.

Stakeholder Impact

• Shareholders: Positive alignment of director interests with long-term shareholder value.

Key Dates

Recommendation

This Form 4 details a routine equity grant to a non-employee director as part of their compensation, which is a standard practice to align director interests with long-term shareholder value. It does not present new information that would significantly alter the investment thesis for Cencora, Inc. (COR), thus a 'hold' recommendation remains appropriate based solely on this filing.

Keywords

Cencora, COR, Form 4, Insider Trading, Restricted Stock Units, RSU, Director Compensation, Equity Grant, Lauren M. Tyler